Live tracker

Peptide Legal Status Tracker

The FDA’s peptide rules are moving fast in 2026, and most posts get them wrong. Here’s what’s actually true right now, no legalese, every change dated.

Last updated: November 18, 2026

FDA-approvedIn FDA trialsPCAC recommendedCompoundableAwaiting FDA reviewNot recommendedRestricted
PeptideAlso known asStatusWhat that means today
PT-141Bremelanotide, VyleesiFDA-approvedFDA approved Vyleesi in June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
SemaglutideWegovy, OzempicFDA-approvedFDA approved Wegovy for chronic weight management in June 2021, and FDA reports the semaglutide shortage is resolved, ending the period when broad compounding of copies was tolerated.
TesamorelinEgriftaFDA-approvedFDA approved Egrifta in November 2010 for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
TirzepatideZepbound, MounjaroFDA-approvedFDA approved Zepbound for chronic weight management on November 8, 2023, and FDA reports the tirzepatide shortage is resolved.
RetatrutideLY3437943, triple agonistIn FDA trialsAs of November 2026 retatrutide is not FDA-approved; Lilly said in July 2026 it plans to submit for FDA approval in the first quarter of 2027, and it runs a narrow compassionate-use program.
BPC-157Body Protection Compound 157PCAC recommendedFDA moved BPC-157 off its Category 2 restricted list in April 2026, and on July 23, 2026 the PCAC voted 8-6 (1 abstention) to recommend it for the 503A Bulks List for ulcerative colitis. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
EpitalonEpithalon, Ala-Glu-Asp-GlyPCAC recommendedOn July 24, 2026 the PCAC voted 7-4 (1 abstention) to recommend Epitalon for the 503A Bulks List for insomnia. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
KPVLys-Pro-Val tripeptide (alpha-MSH 11-13)PCAC recommendedOn July 23, 2026 the PCAC voted 8-6 (1 abstention) to recommend KPV for the 503A Bulks List for wound healing and inflammatory conditions. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
MOTS-cMitochondrial-derived peptidePCAC recommendedOn July 23, 2026 the PCAC voted 7-5 (2 abstentions) to recommend MOTS-c for the 503A Bulks List for obesity and osteoporosis. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
SemaxACTH(4-7)-Pro-Gly-ProPCAC recommendedOn July 24, 2026 the PCAC voted 8-5 (1 abstention) to recommend Semax for the 503A Bulks List for cerebral ischemia, migraine and trigeminal neuralgia. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
TB-500Thymosin beta-4 fragmentPCAC recommendedAfter TB-500 left FDA's Category 2 list in April 2026, the PCAC voted 8-6 (1 abstention) on July 23, 2026 to recommend it for the 503A Bulks List for wound healing. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
SermorelinGHRH(1-29), formerly GerefCompoundableFDA withdrew the Geref approvals in June 2009 at the maker's request and determined in March 2013 that they were not withdrawn for safety or effectiveness reasons, which compounders cite as the basis for 503A compounding.
GHK-CuCopper tripeptide-1Awaiting FDA reviewInjectable GHK-Cu was removed from FDA's Category 2 list in April 2026 but is not on the 503A Bulks List; the PCAC is scheduled to review it at a meeting before the end of February 2027.
CJC-1295Long-acting GHRH analog (with or without DAC)Not recommendedOn December 4, 2024 the PCAC voted 0-13 against adding CJC-1295 (free base) to the 503A Bulks List, agreeing with FDA, and the related salt forms were also rejected.
DSIPEmideltide, delta sleep-inducing peptideNot recommendedOn July 24, 2026 the PCAC voted 6-7 (1 abstention) against adding emideltide (DSIP) to the 503A Bulks List for opioid withdrawal, insomnia and narcolepsy, the only peptide rejected at that meeting.
IpamorelinGhrelin receptor agonist (GH secretagogue)Not recommendedOn October 29, 2024 the PCAC voted 0-12 (1 abstention) against adding ipamorelin to the 503A Bulks List, and as of FDA's April 2026 update ipamorelin acetate remains on the Category 2 list for 503B outsourcing facilities.

Get notified when a peptide's status changes

The FDA and PCAC keep moving the goalposts. We’ll email you the moment a peptide you care about changes category. Plain English, no hype.

How we got here: the 2026 timeline

  1. Feb 27, 2026HHS Secretary announces intent to loosen restrictions on several peptides (policy direction, not a rule).
  2. Apr 15, 2026FDA formally updates its Section 503A list: 12 peptides removed from Category 2.
  3. Apr 23, 2026BPC-157 officially comes off the Category 2 restricted list.
  4. Jul 23–24, 2026PCAC votes to recommend 6 of 7 peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-C, Semax and Epitalon. DSIP is not recommended. The votes are advisory.
  5. Aug 24, 2026FDA issues warning letters to five online "research use only" peptide sellers, treating products such as semaglutide, tirzepatide, retatrutide, tesamorelin, SS-31 and PT-141 as unapproved new drugs. The letters do not change any peptide’s compounding status.
  6. Oct 15, 2026HHS and the FDA send an "interim access policy for compounding using certain peptides" to the White House (OMB) for review. The filing has no details; the AP reports it would let pharmacies compound some popular peptides, including BPC-157, under enforcement discretion. Not in effect yet.
  7. Oct 28, 2026HHS files an interim enforcement discretion policy (published in the Federal Register on Oct 30): it does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding BPC-157, TB-500, KPV, MOTS-C, Semax or Epitalon under set conditions. Not FDA approval, not binding, and states may differ.
  8. Nov 13, 2026The two-week public comment window on the HHS policy closes. The policy itself is unchanged: as of November 18, 2026, HHS had not published a revised or final version.
  9. NextFDA notice-and-comment rulemaking to decide whether to add the six peptides to the 503A Bulks List. As of November 18, 2026, the FDA had not proposed adding them.

Common questions

Is BPC-157 legal in 2026?

As of April 23, 2026, BPC-157 is no longer on the FDA’s Category 2 restricted list, and on July 23, 2026 the Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 to recommend adding it to the 503A Bulks List. That vote is advisory: the FDA still has to complete rulemaking, and as of November 18, 2026 it had not proposed adding BPC-157. In a notice published October 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions, including a patient-specific prescription. That policy is interim and not binding, and states may differ. BPC-157 is not an FDA-approved drug and is not a legal over-the-counter supplement. The route this policy describes is a prescription from a licensed provider filled by a compounding pharmacy.

What does “Category 2” mean?

Category 2 was the FDA’s list of bulk drug substances with significant safety concerns that compounding pharmacies could not use. Being removed from Category 2 is one step. It is separate from being approved for 503A compounding, and separate again from full FDA drug approval.

Are compounded semaglutide and tirzepatide still available?

Semaglutide and tirzepatide are FDA-approved as branded drugs (Wegovy/Ozempic and Zepbound/Mounjaro), and the FDA has declared both shortages resolved. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list; the comment period was extended to July 30, 2026, and as of November 18, 2026 no final determination had been published. Patient-specific options vary, so check with a licensed provider.